InspireMD

InspireMD reported adjusted earnings of $-0.17 per share, slightly above the EPS expectation, but significantly missed the revenue forecast ($1.77 million vs. $2.54 million expected). The voluntary recall of C‑Guard Prime 135 weighed on U.S. sales and led to customer credits and inventory write‑downs; international revenue rose 21%. Management plans about a 20% workforce reduction to save roughly $9 million annually, expects key approval decisions in Q4 2026, and is targeting a possible reintroduction of the revised product in H1 2027. » More on de.investing.com

InspireMD reported an adjusted loss of $0.17 per share for Q2 2026, slightly beating the EPS estimate but missing revenue forecasts significantly with $1.77 million (estimate $2.54 million). A voluntary recall of the C‑Guard Prime 135 weighed on U.S. sales, led to customer credits and inventory write‑downs, while international revenue rose 21%. Management expects key FDA decisions in Q4 2026 and a possible reintroduction of the revised system in H1 2027. InspireMD plans roughly a 20% workforce reduction to cut costs (annual savings about $9 million); cash on hand fell to $30.4 million. The stock fell about 6% in premarket trading. » More on de.investing.com

InspireMD reports Q1 2026 revenue of $3.4 million (+122% YoY) and an EPS better than expected at -$0.16. Despite the results, the stock fell 8.52% in pre-market trading after a temporary suspension of US sales of CGuard Prime. The company withdrew its full-year revenue guidance, cites higher operating costs, and plans to resume US operations after receiving FDA approval for the original CGuard system. In the short term, margin pressure and revenue risks loom due to the operational pause. » More on de.investing.com